Growth Metrics

Integra Lifesciences Holdings (IART) Free Cash Flow (2016 - 2026)

Integra Lifesciences Holdings' Free Cash Flow history spans 17 years, with the latest figure at -$5.4 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 125.53% to -$5.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$31.1 million, a 224.39% decrease, with the full-year FY2025 number at -$31.1 million, down 224.39% from a year prior.
  • Free Cash Flow hit -$5.4 million in Q4 2025 for Integra Lifesciences Holdings, down from $25.8 million in the prior quarter.
  • Over the last five years, Free Cash Flow for IART hit a ceiling of $84.7 million in Q2 2021 and a floor of -$40.2 million in Q1 2025.
  • Historically, Free Cash Flow has averaged $27.7 million across 5 years, with a median of $23.4 million in 2024.
  • Biggest five-year swings in Free Cash Flow: surged 1352.99% in 2021 and later crashed 13906.53% in 2025.
  • Tracing IART's Free Cash Flow over 5 years: stood at $41.8 million in 2021, then soared by 69.36% to $70.9 million in 2022, then tumbled by 51.73% to $34.2 million in 2023, then crashed by 38.21% to $21.1 million in 2024, then plummeted by 125.53% to -$5.4 million in 2025.
  • Business Quant data shows Free Cash Flow for IART at -$5.4 million in Q4 2025, $25.8 million in Q3 2025, and -$11.2 million in Q2 2025.